Home » EU Issues Draft Guidance on Marketing Authorization of Transdermal Patches
EU Issues Draft Guidance on Marketing Authorization of Transdermal Patches
October 2, 2012
Manufacturers of transdermal patches should minimize the amount of residual drug substance in the patch as much as possible to avoid patient and environmental safety risks, according to a new European Medicines Agency (EMA) draft guideline.
To View This Article:
Subscribe To International Medical Device Regulatory Monitor